Results 191 to 200 of about 1,057,642 (298)
LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li +12 more
wiley +1 more source
CD4+ T-lymphocytes in human saccular intracranial aneurysm walls are associated with aneurysm rupture. [PDF]
Firtser N +6 more
europepmc +1 more source
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He +17 more
wiley +1 more source
Actin conformation dynamics precede force generation in cytotoxic T lymphocytes
Lippert A +6 more
europepmc +2 more sources
Bexarotene signaling in human B and T lymphocytes induces gut-homing receptor expression. [PDF]
Kaiser S +6 more
europepmc +1 more source
Pathogenic Role of FGFR3 Autoantibodies in Small Fiber Neuropathy
Autoantibodies against fibroblast growth factor receptor 3 (FGFR3) are identified as pathogenic drivers of pain in small fiber neuropathy. By binding to sensory neurons in dorsal root ganglia, FGFR3 autoantibodies activate MAPK signaling and induce hyperexcitability and mechanical hypersensitivity, establishing FGFR3 autoantibodies as a therapeutic ...
Lyuba Y. Salih +12 more
wiley +1 more source
CD38 promotes LPS-induced innate-like activation and proliferation of CD8<sup>+</sup> T lymphocytes in aged mice. [PDF]
Santiago-Cruz W +6 more
europepmc +1 more source
Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome
Pharmacological SUMOylation inhibition (SUMOi) counteracts tumor immune evasion by unmasking an immunogenic HLA‐I peptide and neoepitope repertoire. By restoring HLA‐I ligand availability through increased antigen processing and presentation, enhanced proteasomal cleavage, and modulated TAP1 peptide affinity, SUMOi boosts tumor immunogenicity ...
Uta M. Demel +19 more
wiley +1 more source

